company background image
EVAX

Evaxion Biotech NasdaqCM:EVAX Stock Report

Last Price

US$2.23

Market Cap

US$53.1m

7D

4.9%

1Y

-46.5%

Updated

01 Dec, 2022

Data

Company Financials +
EVAX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

EVAX Stock Overview

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.

Evaxion Biotech A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evaxion Biotech
Historical stock prices
Current Share PriceUS$2.23
52 Week HighUS$4.84
52 Week LowUS$1.51
Beta0
1 Month Change-10.80%
3 Month Change0%
1 Year Change-46.52%
3 Year Changen/a
5 Year Changen/a
Change since IPO-77.45%

Recent News & Updates

Evaxion Biotech names Per Norlén as CEO

Oct 05

Recent updates

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

Oct 27
Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Jun 29
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Shareholder Returns

EVAXUS BiotechsUS Market
7D4.9%2.7%1.4%
1Y-46.5%-10.3%-16.1%

Return vs Industry: EVAX underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: EVAX underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is EVAX's price volatile compared to industry and market?
EVAX volatility
EVAX Average Weekly Movement13.2%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: EVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: EVAX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200861Per Norlenhttps://www.evaxion-biotech.com

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.

Evaxion Biotech A/S Fundamentals Summary

How do Evaxion Biotech's earnings and revenue compare to its market cap?
EVAX fundamental statistics
Market CapUS$53.15m
Earnings (TTM)-US$24.67m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EVAX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$24.67m
Earnings-US$24.67m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio48.2%

How did EVAX perform over the long term?

See historical performance and comparison